Stock Report

All about this stock under one free report Last Updated: 09-Nov-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Senores Pharmaceuticals Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: SENORES | BSE: 544319

₹1,175.00

up-down-arrow ₹-19.00 (-1.59%)

As on 09-Nov-2026IST

Market cap

info icon

₹5,402 Cr

Revenue (TTM)

info icon

₹722 Cr

P/E Ratio

info icon

40.5

P/B Ratio

info icon

5.4

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 6.73 24.94 43.39 161.60 --
EBIT 8.19 41.10 90.76 132.61 --
Net Profit 28.55 21.96 53.23 143.35 --
EPS 28.56 21.96 53.23 42.86 --
Book Value -- -- 18.71 63.52 --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-26Mar-25
EBIT-Margin info 18.23--24.3121.6718.30
Net Margin info 15.63--18.1717.8813.97
Return on equity info 17.37--13.7914.1411.78
Return on Capital info 13.30----15.6611.94
Return on Assets info 7.98--9.258.646.43
Debt to Equity (x) info ----0.210.350.39

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
--
15.66
11.94
12.31
18.56
Peer Median
--
14.03
16.46
15.49
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

13.79

Higher than Peers by 3.01

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
13.79
14.14
11.78
26.19
20.55
Peer Median
10.78
13.45
13.87
14.72
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

9.25

Higher than Peers by 1.44

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
9.25
8.64
6.43
8.86
8.89
Peer Median
7.81
7.94
8.04
7.19
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

24.31

Higher than Peers by 14.69

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
24.31
21.67
18.30
14.72
30.82
Peer Median
9.62
20.82
10.05
10.28
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

18.17

Higher than Peers by 7.96

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
18.17
17.88
13.97
15.05
21.61
Peer Median
10.21
11.88
9.11
6.78
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
--
24.15
18.88
19.91
28.90
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

43.39

Higher than Peers by 35.93

Year on year growth in net sales

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
43.39
58.85
85.65
507.07
149.38
Peer Median
7.46
24.06
7.17
10.56
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

90.76

Higher than Peers by 86.90

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
90.76
88.13
130.79
189.87
773.38
Peer Median
3.87
30.32
12.05
6.17
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

53.23

Higher than Peers by 40.33

Year on year growth in profit after tax

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
53.23
108.31
78.36
287.88
750.96
Peer Median
12.90
29.80
22.15
27.97
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

53.23

Higher than Peers by 46.44

Year on year growth in earnings per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
53.23
97.01
23.33
20.01
657.94
Peer Median
6.79
22.75
8.80
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
--
18.71
284.87
348.95
24.35
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

0.21

Higher than Peers by 0.20

Total debt / Net worth

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
0.21
0.35
0.39
1.22
1.34
Peer Median
0.02
0.17
0.03
0.05
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
--
0.03
0.04
0.16
0.18
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

1.86

Lower than Peers by 0.64

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
1.86
1.92
3.00
1.01
0.99
Peer Median
2.50
2.23
2.20
1.93
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

1.62

Lower than Peers by 0.15

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
1.62
1.71
2.77
0.86
0.93
Peer Median
1.77
1.70
1.72
1.59
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

7.02

Lower than Peers by 3.33

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
7.02
7.36
4.27
3.64
6.82
Peer Median
10.35
11.31
12.28
12.45
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

35.06

Higher than Peers by 7.86

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
35.06
51.34
31.11
52.21
62.56
Peer Median
27.19
32.77
26.23
23.97
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.49

Lower than Peers by 0.17

Sales / Average Total Assets

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
0.49
0.45
0.44
0.58
0.37
Peer Median
0.66
0.64
0.74
0.88
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
--
129.44
108.09
114.09
215.56
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
--
42.09
43.08
34.45
31.54
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
--
218.97
182.04
217.67
296.18
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
--
-47.43
-30.87
-69.13
-49.08
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

40.47

Lower than Peers by 4.85

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
40.47
30.25
45.04
--
--
Peer Median
45.32
49.26
39.17
40.74
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

5.39

Higher than Peers by 1.64

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
5.39
3.74
3.35
--
--
Peer Median
3.74
5.03
3.61
3.87
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
--
--
--
--
--
Peer Median
0.12
0.12
0.19
0.20
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

23.14

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
23.14
16.98
23.47
5.99
4.31
Peer Median
--
42.74
28.79
25.41
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

5,402

Higher than Peers by 108

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Senores Pharmaceuticals
5,402
3,490
2,638
--
--
Peer Median
5,294
5,352
3,944
2,959
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...

Informed fund ideas, better judgment. Every month. Mutual Fund Insight, every month since October 2002.

Take charge. Know more. Keep more. Mutual Fund Insight helps you do all three — every month